Drug Profile

Saxagliptin - AstraZeneca

Alternative Names: BMS-477118; Onglyza; OPC-262

Latest Information Update: 05 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bristol-Myers Squibb
Developer AstraZeneca; Bristol-Myers Squibb; Otsuka Pharmaceutical
Class Adamantanes; Antihyperglycaemics; Azabicyclo compounds; Dipeptides; Nitriles; Organic bridged compounds; Piperidines; Small molecules
Mechanism of Action Dipeptidyl peptidase 4 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

09 Sep 2024 Pharmacodynamics, efficacy and adverse events data from phase III T2NOW trial for Type 2 diabetes mellitus presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD-2024)
03 Jan 2024 AstraZeneca completes phase III trials for Type 2 diabetes mellitus (Adjunctive treatment, In adolescents, In children) in USA, Australia, Argentina, United Kingdom, Ukraine, Turkey, Thailand, Taiwan, Russia, Romania, Philippines, New Zealand, Mexico, Malaysia, South Korea, Italy, Israel, India, Colombia, Chile, Brazil, Canada, Finland, Poland (PO) (NCT03199053)
08 Mar 2022 Saxagliptin is still in phase III trials for Type 2 diabetes mellitus (Adjunctive treatment, In adolescents, In children) in USA, Australia, Argentina, United Kingdom, Ukraine, Turkey, Thailand, Taiwan, Russia, Romania, Philippines, New Zealand, Mexico, Malaysia, South Korea, Italy, Israel, India, Colombia, Chile, Brazil, Canada, Finland, Poland (PO) (NCT03199053)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com